Ivermectin gets push in vaccine summit | Inquirer News

Ivermectin gets push in vaccine summit

/ 04:46 AM May 03, 2021

MANILA, Philippines — A vaccine summit organized by business groups shifted to discussions on the controversial drug ivermectin, with the president of the Employers Confederation of the Philippines (Ecop) expressing his frustration at drug regulators for “blocking” the use of the antiparasitic drug to treat COVID-19.

The three-hour online summit held on Friday was organized by the International Chamber of Commerce and the Philippine Chamber of Commerce and Industry.

Dr. Allan Landrito, an ivermectin advocate and founder of Concerned Doctors and Citizens of the Philippines, spoke during the panel discussion.

Article continues after this advertisement

“It’s really helping a lot in terms of prevention and treatment of COVID-19,” Landrito said.

FEATURED STORIES

But the Food and Drug Administration (FDA) has yet to approve the use of ivermectin, either as COVID prophylaxis or treatment.

Landrito said he had given ivermectin to people, of whom 95 percent showed that it was safe and effective in achieving “natural immunity” to the virus.

Article continues after this advertisement

Sergio Ortiz-Luis Jr., president of Ecop, said several countries had been using ivermectin, yet the FDA had “made it criminal to use ivermectin” in the Philippines.

“Why go [to great] lengths of blocking it?” he asked.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Ivermectin

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.